华兰生物,002007,收入构成,报告日期,2019-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1292,-- ,-- ,--,0% 静注丙球,89082,36803,52279,58.69%,21.8% 其他(补充),-- ,330,-- ,--,0% 其他血液制品,77448,30891,46557,60.11%,19.42% 疫苗,104319,15618,88702,85.03%,37% 人血白蛋白,97853,45625,52228,53.37%,21.78% 华兰生物,002007,收入构成,报告日期,2019-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,795,-- ,-- ,--,0% 静注丙球,47247,18593,28653,60.65%,35.26% 疫苗,1197,-- ,-- ,--,0% 其他血液制品,40002,15209,24792,61.98%,30.51% 其他(补充),-- ,122,-- ,--,0% 人血白蛋白,51020,23201,27819,54.53%,34.23% 华兰生物,002007,收入构成,报告日期,2018-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),730,363,367,50.32%,0.18% 疫苗,79774,13032,66742,83.66%,31.93% 人血白蛋白,102541,48546,53996,52.66%,25.83% 静注丙球,60409,24034,36375,60.21%,17.4% 其他,78235,26685,51551,65.89%,24.66% 华兰生物,002007,收入构成,报告日期,2018-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 人血白蛋白,47267,21921,25346,53.62%,35.12% 其他,40212,13853,26360,65.55%,36.52% 其他(补充),389,215,174,44.76%,0.24% 静注丙球,27205,10696,16510,60.69%,22.87% 疫苗,5041,1251,3790,75.18%,5.25% 华兰生物,002007,收入构成,报告日期,2017-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 疫苗,28098,8560,19537,69.53%,13.25% 人血白蛋白,92010,37549,54461,59.19%,36.94% 其他,900,-- ,-- ,--,0% 静注丙球,67703,24728,42975,63.48%,29.15% 其他血液制品,48107,17649,30458,63.31%,20.66% 华兰生物,002007,收入构成,报告日期,2017-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 静注丙球,32747,11145,21601,65.97%,33.12% 其他(补充),454,180,274,60.38%,0.42% 其他,20920,7326,13594,64.98%,20.84% 人血白蛋白,43812,16854,26957,61.53%,41.33% 疫苗,3351,550,2801,83.59%,4.29% 华兰生物,002007,收入构成,报告日期,2016-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1097,-- ,-- ,--,0% 疫苗,10896,5143,5753,52.8%,4.93% 其他血液制品,40225,14163,26062,64.79%,22.33% 静注丙球,73089,28086,45003,61.57%,38.55% 人血白蛋白,68160,28243,39917,58.56%,34.19% 华兰生物,002007,收入构成,报告日期,2016-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),304,82,222,72.94%,0.41% 其他,17392,5300,12092,69.53%,22.16% 疫苗,1246,686,560,44.92%,1.03% 静注丙球,32412,11843,20570,63.46%,37.69% 人血白蛋白,34302,13175,21126,61.59%,38.71% 华兰生物,002007,收入构成,报告日期,2015-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),658,242,415,63.18%,0.49% 其他,29241,10515,18726,64.04%,21.96% 疫苗,11117,7850,3267,29.39%,3.83% 静注丙球,42179,16029,26150,62%,30.66% 人血白蛋白,63981,27258,36724,57.4%,43.06% 华兰生物,002007,收入构成,报告日期,2015-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),297,111,186,62.48%,0.45% 静注丙球,19932,7591,12341,61.92%,30.23% 其他,14350,3527,10823,75.42%,26.51% 人血白蛋白,28658,12489,16168,56.42%,39.61% 疫苗,2473,1169,1304,52.72%,3.19% 华兰生物,002007,收入构成,报告日期,2014-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 疫苗,16013,7714,8298,51.82%,10.79% 其他(补充),1242,753,490,39.41%,0.64% 静注丙球,43135,13996,29140,67.55%,37.89% 其他,20413,7879,12533,61.4%,16.3% 人血白蛋白,43546,17093,26453,60.75%,34.39% 华兰生物,002007,收入构成,报告日期,2014-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),916,460,457,49.84%,1.3% 其他,8832,2043,6789,76.87%,19.32% 其他疫苗,1792,806,986,55.03%,2.81% 静注丙球,21322,6680,14641,68.67%,41.66% 人血白蛋白,20030,7762,12268,61.25%,34.91% 华兰生物,002007,收入构成,报告日期,2013-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),170,63,107,62.9%,0.16% 其他,17480,6036,11444,65.47%,16.85% 其他疫苗,15590,8285,7306,46.86%,10.76% 甲流疫苗,-- ,-- ,-- ,--,0% 静注丙球,40827,14745,26082,63.88%,38.41% 人血白蛋白,37694,14727,22967,60.93%,33.82% 华兰生物,002007,收入构成,报告日期,2013-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),213,3,210,98.74%,0.65% 其他,7493,2719,4774,63.72%,14.7% 其他疫苗,2752,684,2068,75.14%,6.37% 甲流疫苗,-- ,-- ,-- ,--,0% 静注丙球,22218,7660,14558,65.52%,44.82% 人血白蛋白,17873,7005,10868,60.81%,33.46% 华兰生物,002007,收入构成,报告日期,2012-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),67,28,40,58.7%,0.08% 其他,15205,7894,7311,48.08%,15.34% 其他疫苗,14188,7275,6914,48.73%,14.51% 甲流疫苗,10586,-- ,-- ,--,0% 静注丙球,23895,9389,14506,60.71%,30.44% 人血白蛋白,33305,14428,18877,56.68%,39.62% 华兰生物,002007,收入构成,报告日期,2012-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 人血白蛋白,13717,5014,8702,63.44%,43.73% 其他业务,30,129,-99,-330.1%,-0.5% 其他(主营),8330,4368,3962,47.57%,19.91% 其他疫苗,150,102,48,31.95%,0.24% 静注丙球,10947,3709,7238,66.12%,36.37% 甲流疫苗,10586,-- ,-- ,--,0% 材料销售,50,0,50,99.51%,0.25% 华兰生物,002007,收入构成,报告日期,2011-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(主营),14298,5314,8984,62.83%,13.31% 其他(其他业务),30,3,27,90.47%,0.04% 材料销售,-- ,-- ,-- ,--,0% 其他疫苗,20367,5046,15322,75.23%,22.69% 甲流疫苗,1172,0,1172,100%,1.74% 静注丙球,26680,7912,18768,70.35%,27.8% 人血白蛋白,33592,10351,23241,69.19%,34.42% 华兰生物,002007,收入构成,报告日期,2011-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),1,-- ,-- ,--,0% 其他,6959,2272,4687,67.35%,13.97% 其他疫苗,4103,719,3385,82.49%,10.09% 甲流疫苗,1172,143,1029,87.83%,3.07% 静注丙球,14757,4477,10280,69.66%,30.64% 人血白蛋白,19992,5823,14169,70.87%,42.23% 华兰生物,002007,收入构成,报告日期,2010-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,17414,5369,12045,69.17%,12.45% 其他疫苗,20299,2901,17398,85.71%,17.98% 甲流疫苗,30873,3781,27092,87.75%,28% 静注丙球,27416,7763,19653,71.69%,20.31% 人血白蛋白,30150,9566,20585,68.27%,21.27% 华兰生物,002007,收入构成,报告日期,2010-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 静注丙球,12086,3524,8562,70.84%,17.69% 流脑疫苗,2733,261,2472,90.46%,5.11% 人血白蛋白,12442,4200,8241,66.24%,17.03% 流感疫苗,24455,2734,21720,88.82%,44.87% 其他,9795,2384,7411,75.66%,15.31% 华兰生物,002007,收入构成,报告日期,2009-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,9875,1898,7977,80.78%,8.6% 材料销售,82,53,29,35.24%,0.03% 其他(补充),4,0,3,93.52%,0% 流感疫苗,71402,10841,60561,84.82%,65.28% 静注丙球,14385,4466,9919,68.96%,10.69% 人血白蛋白,26302,12026,14276,54.28%,15.39% 华兰生物,002007,收入构成,报告日期,2009-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其它,2041,344,1697,83.14%,13.5% 流感疫苗,-575,-491,-84,14.54%,-0.67% 静注丙球,7491,2184,5307,70.85%,42.22% 人血白蛋白,11015,5365,5650,51.3%,44.95% 华兰生物,002007,收入构成,报告日期,2008-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他业务,57,-- ,-- ,--,0% 其他(主营),4345,2037,2308,53.12%,8.09% 销售材料,32,4,28,87.95%,0.1% 流感疫苗,7327,2398,4930,67.28%,17.29% 静注丙球,12990,2779,10210,78.61%,35.81% 人血白蛋白,22766,11726,11040,48.49%,38.72% 华兰生物,002007,收入构成,报告日期,2008-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务费及售鸡胚等,109,127,-18,-16.51%,-0.16% 销售材料,2,-- ,-- ,--,0% 其他,1864,848,1017,54.54%,8.96% 静注丙球,6281,1408,4873,77.58%,42.93% 人血白蛋白,11466,5989,5478,47.77%,48.26% 华兰生物,002007,收入构成,报告日期,2007-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,5633,3375,2258,40.08%,11.98% 静注丙球,9040,2549,6491,71.8%,34.43% 人血白蛋白,20392,10288,10104,49.55%,53.6% 华兰生物,002007,收入构成,报告日期,2007-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其它,2898,1866,1032,35.61%,12.61% 静注丙球,4463,1598,2864,64.18%,35% 人血白蛋白,9756,5470,4286,43.93%,52.38% 华兰生物,002007,收入构成,报告日期,2006-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,5471,4028,1443,26.38%,10.54% 静注丙球,4088,2822,1266,30.97%,9.25% 人血白蛋白,25740,14762,10978,42.65%,80.21% 华兰生物,002007,收入构成,报告日期,2006-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1339,886,453,33.8%,11.7% 静注丙球,1124,660,464,41.3%,12% 人血白蛋白,6333,3381,2952,46.62%,76.31% 华兰生物,002007,收入构成,报告日期,2006-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,2672,1946,726,27.16%,9.99% 静注丙球,1695,1234,461,27.17%,6.34% 人血白蛋白,13282,7202,6080,45.77%,83.67% 华兰生物,002007,收入构成,报告日期,2006-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1161,883,278,23.94%,8.3% 静注丙球,866,703,163,18.87%,4.88% 人血白蛋白,6990,4083,2907,41.59%,86.82% 华兰生物,002007,收入构成,报告日期,2005-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,4334,3504,830,19.14%,6.91% 静注丙球,2953,2599,354,11.99%,2.95% 人血白蛋白,28841,18017,10824,37.53%,90.14% 华兰生物,002007,收入构成,报告日期,2005-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,223,147,77,34.28%,2.22% 破伤风免疫球蛋白,569,411,158,27.82%,4.59% 凝血酶原复合物,418,281,137,32.79%,3.97% 人免疫球蛋白,109,184,-75,-68.72%,-2.18% 静注丙球,860,673,187,21.75%,5.42% 人血白蛋白,6388,3421,2967,46.44%,85.98% 华兰生物,002007,收入构成,报告日期,2005-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,321,202,118,36.89%,2.33% 人破伤风免疫球蛋白,690,563,127,18.4%,2.5% 冻干人凝血酶原复合物,808,553,255,31.59%,5.04% 肌注丙球,169,226,-57,-33.48%,-1.12% 静注丙球,1207,1091,115,9.57%,2.28% 人血白蛋白,14178,9668,4510,31.81%,88.96% 华兰生物,002007,收入构成,报告日期,2005-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,751,597,155,20.58%,6.63% 肌注丙球,82,106,-24,-28.83%,-1.02% 静注丙球,536,508,28,5.25%,1.21% 人血白蛋白,7590,5419,2171,28.6%,93.18% 华兰生物,002007,收入构成,报告日期,2004-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 人血白蛋白,28198,18897,9301,32.98%,94.73% 其他,2251,2002,249,11.08%,2.54% 肌注丙球,399,357,42,10.47%,0.43% 静注丙球,1231,1004,227,18.41%,2.31% 华兰生物,002007,收入构成,报告日期,2004-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,413,314,99,24.01%,4.55% 肌注丙球,38,43,-5,-12.06%,-0.21% 静注丙球,297,247,50,16.78%,2.28% 人血白蛋白,6688,4650,2037,30.46%,93.38% 华兰生物,002007,收入构成,报告日期,2004-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1211,1093,118,9.77%,2.23% 肌注丙球,159,161,-2,-1.29%,-0.04% 静注丙球,627,500,127,20.28%,2.39% 人血白蛋白,14392,9320,5071,35.24%,95.42% 华兰生物,002007,收入构成,报告日期,2003-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,1391,965,426,30.63%,4.73% 静注丙球,1667,1099,569,34.11%,6.32% 肌注丙球,1123,964,159,14.17%,1.77% 人血白蛋白,21109,13261,7848,37.18%,87.18% 华兰生物,002007,收入构成,报告日期,2002-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,653,370,283,43.34%,4.85% 静注丙球,1548,885,663,42.82%,11.36% 肌注丙球,289,272,17,5.95%,0.29% 人血白蛋白,14776,9903,4873,32.98%,83.5% 华兰生物,002007,收入构成,报告日期,2001-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他,460,260,201,43.58%,5.25% 静注丙球,1349,715,634,47.02%,16.6% 肌注丙球,651,424,226,34.8%,5.92% 人血白蛋白,9977,7216,2761,27.67%,72.23%